Stegall M D, Morris R E, Alloway R R, Mannon R B
Departments of Surgery and Immunology, von Liebig Transplant Center, Mayo Clinic, Rochester, MN.
Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA.
Am J Transplant. 2016 Apr;16(4):1094-101. doi: 10.1111/ajt.13582. Epub 2016 Jan 5.
The development of new immunosuppressive drugs has slowed markedly over the past several years, and the outlook that improved therapy will be available to the next generation of transplant recipients is bleak. In this viewpoint, the authors outline some of important barriers to new drug development and suggest specific steps that the transplant community can take to overcome them.
在过去几年中，新型免疫抑制药物的研发明显放缓，下一代移植受者有望获得更好治疗的前景黯淡。在这一观点中，作者概述了新药研发的一些重要障碍，并提出了移植界可以采取的克服这些障碍的具体措施。
